Company Overview and News

 
LPI Capital likely to repeat strong 3Q performance in 4Q

2018-10-12 theedgemarkets
LPI Capital Bhd (Oct 11, RM16.52) Maintain buy with an unchanged target price (TP) of RM18.90: LPI Capital Bhd saw a favourable quarter in the third quarter of financial year 2018 (3QFY18), with net profit coming in at RM91.8 million (+40% quarter-on-quarter [q-o-q]; flat year-on-year [y-o-y]).
8621

 
LPI Capital 3Q net profit drops slightly on lower revenue

2018-10-11 theedgemarkets
KUALA LUMPUR: LPI Capital Bhd’s net profit saw a marginal 0.4% drop to RM91.81 million in the third quarter ended Sept 30, 2018 (3QFY18) from RM92.17 million a year ago, on lower revenue.
8621 BSMAF 1818

 
KLCI to track global losses, hurdle at 1,750

2018-10-10 theedgemarkets
KUALA LUMPUR (Oct 11): The FBM KLCI is expected the track the overnight losses at global markets and remain lacklustre with immediate hurdle at the 1,750.
TGLVY 5104 8621 7113 MYPRY TPGVF 5014

 
LPI Capital, Top Glove, Red Ideas, MCE, MAHB, Gamuda, MMC Corp, CNI Holdings and mTouche Technology

2018-10-10 theedgemarkets
KUALA LUMPUR (Oct 10): Based on corporate announcements and news flow today, companies in focus on Thursday (Oct 11) may include: LPI Capital Bhd, Top Glove Corp Bhd, Red Ideas Holdings Bhd, MCE Holdings Bhd, Malaysia Airports Holdings Bhd (MAHB), Gamuda Bhd, MMC Corp Bhd, CNI Holdings Bhd and mTouche Technology Bhd
TGLVY 5104 8621 7113 7004 MYPRY TPGVF 5014

 
KLCI erases earlier loss, crosses 1,800-level

2018-09-27 theedgemarkets
KUALA LUMPUR (Sept 27): The FBM KLCI erased its earlier losses and rose at mid-morning to cross the 1,800-point level.
5072 8621 7158 BATS 4162 7215 2089 5199 5347 3301 7668 TNABY AXXTF HIPEF PNAGF UPBMF 1163 5202 8311 6033 2593 5139 PNADF 0900 6888 TNABF 3719

 
KLCI pares loss, sentiment stays tepid

2018-09-26 theedgemarkets
KUALA LUMPUR (Sept 26): The FBM KLCI pared some of its losses at mid-morning today as the local index tracked regional markets.
HLFBF 5183 PECGF 7060 8621 7036 1082 BATS 4162 5256 5199 7233 5347 3026 TNABY 2836 TNABF HIPEF 1929

 
KLCI up 0.53%, stays above 1,800-level

2018-09-19 theedgemarkets
KUALA LUMPUR (Sept 19): The FBM KLCI rose 0.53% at midday break today, tracking the broad-based uptrend at regional markets, while staying above the crucial 1,800-point level.
HLFBF 7052 PBLOF 7060 8621 1082 7113 TPGVF BATS 4162 1163 1295 6033 5199 TGLVY 4588 PNADF 3026 0026 5819 HIPEF PNAGF

 
KLCI falls 0.66% as Trump’s new tariff on China rattles region

2018-09-18 theedgemarkets
KUALA LUMPUR (Sept 18): The FBM KLCI fell 0.66% at midday break, as new tariffs announced by Washington on Chinese imports rattled regional markets.
HLFBF 7052 MLYNF 8621 9679 BATS 4162 2089 1783 1023 5225 IHHHF PNAGF HRGHY MLYBY UPBMF 1082 5681 5168 6033 7123 CIMDF 5238 1155 PNADF SGPBY 0026 Q0F

 
KLCI pares loss, attempts to claw back to 1,800-level

2018-09-18 theedgemarkets
KUALA LUMPUR (Sept 18): The FBM KLCI pared some of its losses at mid-morning today and attempted to claw back to the 1,800-point level.
7052 8621 7113 TPGVF BATS 4162 9334 7123 TGLVY 5139 0900 0026 2836

 
KLCI remains in the red as select blue chips drag

2018-09-04 theedgemarkets
KUALA LUMPUR (Sept 4): The FBM KLCI remained in negative zone at mid-morning today, dragged by losses at select index-linked blue chips.
UPBMF 8621 6432 BATS 4162 2089 5014 8311 5199 7079 7617 KLKBY 5029 2445 4588 4456 3026 6888 MYPRY AXXTF HIPEF 3719

 
Financially distressed firms to be on MSWG's radar

2018-08-27 theedgemarkets
KUALA LUMPUR (Aug 27): The Minority Shareholder Watch Group (MSWG) will include financially distressed companies and China-based companies listed on Bursa Malaysia on its radar by June next year, from 300 listed firms currently.
MLYNF 7113 8621 TPGVF AMMHF 1023 5347 TNABY SMEBF AXXTF MYTEF PNAGF 5183 MLYBY PECGF 4197 6399 5681 6033 CIMDF TGLVY 1155 PNADF 4588 1015 4863 6888 TNABF BSMAF 1818

 
KLCI holds on to marginal gains as Petronas-linked stocks lift

2018-08-15 theedgemarkets
KUALA LUMPUR (Aug 15): The FBM KLCI held on to its marginal gains at mid-morning today, despite the retreat at most regional markets, propped up by Petronas-linked stocks.
APEXF 5161 7090 0090 7192 8621 5681 JCYBF BATS 4162 7034 6033 5101 PNADF 3301 5797 6556 5819 PNAGF

 
KLCI reverses earlier losses, select blue chips lift

2018-08-14 theedgemarkets
KUALA LUMPUR (Aug 14): The FBM KLCI reversed its earlier losses and clawed into positive territory at mid-morning today, lifted by select blue chips including Tenaga Nasional Bhd.
APEXF 7090 8621 5681 7248 6033 2593 7079 PNADF 5347 5225 8613 6645 TNABY TNABF Q0F IHHHF PNAGF

 
KLCI pares loss, attempts to climb higher in line with region

2018-08-01 theedgemarkets
KUALA LUMPUR (Aug 1): The FBM KLCI pared some its loss at mid-morning today and made an attempt to climb higher in line with the gains at most regional markets.
UPBMF 8621 7113 TPGVF BATS 4162 2089 6033 7123 TGLVY 5436 PNADF 5347 0035 0026 5208 TNABY 5819 TNABF PNAGF GEBHF

 
KLCI remains subdued, tracks regional peers

2018-07-30 theedgemarkets
KUALA LUMPUR (July 30): The FBM KLCI remained subdued at the midday break today, tracking its regional peers.
HLFBF APEXF 7090 8621 7036 BATS 4162 5014 5029 3026 5225 3867 1589 2739 IHHHF PNAGF 1082 5681 6033 5139 PNADF 0900 MYPRY Q0F 3719

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...